ClinicalTrials.gg
RecruitingNCT06387225HYPERION-2Updated Nov 19, 2026

Early and Objective Assessment of Neurological Prognosis in Cardiac Arrest Patients

An observational study in Cardiac Arrest, Neurologic Symptoms and Intensive Care Neurological Disorder, sponsored by Nantes University Hospital. Recruiting at 4 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Nantes University Hospital · Observational

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.
Updated Nov 19, 20264 sites added4 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
608
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Heart Arrest with a site in France — 32 open to participants now, 33 under way, 3 of them phase 3. Heart Arrest · France.

Planned enrollment
7th of 47
608 · median 150
Started
2025
with 9 others
Observational
47 of 106
17 open now
Primary completion
2027-05
later than 13 of 32 live
Registered
86th of 106
by date
Lead sponsor
5 of 106
Nantes University Hospital

Among the 106 studies in Heart Arrest with a site in France, this one is the 7th largest by planned enrollment of the 47 observational ones that give a count, is one of 10 that started in 2025, is one of 47 observational ones, reaches primary completion later than 13 of the 32 other live ones, and was the 86th registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

32 of the 106 studies in Heart Arrest with a site in France are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Heart Arrest with a site in France, or all of them as a file.
02

Study summary

Cerebral lesions are responsible for two thirds of deaths in patients admitted to intensive care following cardiac arrest. Patients with neurological lesions should be the priority target for neuroprotective interventions, which are the cornerstone of post-cardiac arrest care (allowing a reduction in the burden of care for patients without this type of lesion). Furthermore, these interventions must be based on a precise assessment of the severity of these brain lesions: carrying out neuro-protective interventions in patients without brain lesions exposes these patients to unnecessary treatment potentially associated with adverse effects without any possible benefit. However, the early assessment of neurological prognosis, particularly on admission to intensive care, is an area where there is little research and where it is not possible to obtain a precise and reproducible assessment. Several tools can be used to assess this prognosis at an early stage: anamnesis and characteristics of the cardiac arrest and the patient's comorbidities, imaging, electrophysiology and biomarkers.

To assess the predictive value of early biomarker testing in patients resuscitated after cardiac arrest, whatever the cause, the investigators plan to conduct a prospective observational multicentre trial.

It is important to bear in mind that the aim of this study is not to assess the long-term prognosis of patients suffering cardiac arrest in order to take measures to limit or discontinue active therapies, but simply to provide a reliable tool, simple and quick to use, in order to be able to identify a sub-population of patients who should be the subject of preferential neuro-protection measures, and conversely to simplify management (moderate temperature control, early cessation of sedation, early extubation) for patients with no neurological lesions.

03

Conditions studied

  • Cardiac Arrest
  • Neurologic Symptoms
  • Intensive Care Neurological Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients will be included on admission to intensive care.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Admitted to intensive care with out-of-hospital cardiac arrest
  • Comatose on admission (defined by a Glasgow score ≤ 8)
  • Informed relative who has consented to the patient's participation in the study or inclusion under emergency procedure if the relative is absent at the time of inclusion

Exclusion criteria

Exclusion Criteria:

  • In-hospital cardiac arrest
  • Age \< 18 years
  • Person under guardianship or legal protection
  • Prior inclusion in the study
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
608 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Dosage of biomarker UCHL-1 (Ubiquitin carboxy-terminal hydrolase L1) at the time of admission to intensive care

    Determine an assay threshold value admission to the intensive care unit to predict membership of a homogeneous group with favorable neurological outcome at D90

    Time frame: at ICU admission

  2. Dosage of biomarker GFAP (Glial fibrillary acidic protein) at the time of admission to intensive care

    Determine an assay threshold value admission to the intensive care unit to predict membership of a homogeneous group with favorable neurological outcome at D90

    Time frame: at ICU admission

  3. Neurological outcome at D90 assessed by modified Rankin scale (mRS)

    Determine an assay threshold value admission to the intensive care unit to predict membership of a homogeneous group with favorable neurological outcome at D90

    Time frame: 90 days after patient enrolment in the study

Secondary outcomes

  1. Dosage of biomarkers UCHL-1 ((Ubiquitin carboxy-terminal hydrolase L1) at the time of admission to intensive care

    Determine prognostic value (positive and negative predictive value (PPV/NPV), positive and negative likelihood ratio (LR+/LR-) of each biomarker separately according to the threshold on admission. Determine the value of combining the two biomarkers at admission.

    Time frame: at ICU admission

  2. Dosage of biomarkers GFAP (Glial fibrillary acidic protein) at the time of admission to intensive care

    Determine prognostic value (positive and negative predictive value (PPV/NPV), positive and negative likelihood ratio (LR+/LR-) of each biomarker separately according to the threshold on admission. Determine the value of combining the two biomarkers at admission.

    Time frame: at ICU admission

  3. Dosage of biomarkers UCHL-1 (Ubiquitin carboxy-terminal hydrolase L1) at 4 hours for recovery of effective cardiac activity (RACS)

    Determine a threshold value at H4 for recovery of effective cardiac activity (RACS) to predict membership of a homogeneous group with a favorable neurological outcome at D90. Determine interest of combining the two biomarkers at H4 of the RACS.

    Time frame: at 4 hours for recovery of effective cardiac activity (RACS)

  4. Dosage of biomarkers GFAP( Glial fibrillary acidic protein) at 4 hours for recovery of effective cardiac activity (RACS)

    Determine a threshold value at H4 for recovery of effective cardiac activity (RACS) to predict membership of a homogeneous group with a favorable neurological outcome at D90. Determine interest of combining the two biomarkers at H4 of the RACS.

    Time frame: at 4 hours for recovery of effective cardiac activity (RACS)

  5. Neurological outcome at D90 assessed by modified Rankin scale (mRS) ranging from 0 to 6

    Determine a threshold value at H4 for recovery of effective cardiac activity (RACS) to predict membership of a homogeneous group with a favorable neurological outcome at D90. A score of 0 to 3 is considered a favorable neurological outcome.

    Time frame: 90 days after patient enrolment in the study

07

Study locations

4 of 4 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for May 2027, 27 months after the start.

Of 169 non-industry observational studies under Heart Arrest, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 96. This study's planned 27 months is below that.

Counting every sponsor, half of 176 studies reached it within 41 months; a quarter within 18 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2024
First posted
Apr 26, 2024
StartActual
Feb 2, 2025
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 4 sites removed
Show 4 added (4 France)
  • CHD Vendée · La Roche-sur-Yon, France
  • CHU Nantes · Nantes, France
  • APHP - Hôpital Cochin · Paris, France
  • CH Saint-Nazaire · Saint-Nazaire, France
Show 4 removed
  • CHD Vendée · La Roche-sur-Yon, France
  • CHU Nantes · Nantes, France
  • APHP - Hôpital Cochin · Paris, France
  • CH Saint-Nazaire · Saint-Nazaire, France
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    4 sites added, 4 sites removed
    Show 4 added (4 France)
    • CHD Vendée · La Roche-sur-Yon, France
    • CHU Nantes · Nantes, France
    • APHP - Hôpital Cochin · Paris, France
    • CH Saint-Nazaire · Saint-Nazaire, France
    Show 4 removed
    • CHD Vendée · La Roche-sur-Yon, France
    • CHU Nantes · Nantes, France
    • APHP - Hôpital Cochin · Paris, France
    • CH Saint-Nazaire · Saint-Nazaire, France
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06387225
Responsible party
Sponsor
First posted
Apr 26, 2024
Start date
Feb 2, 2025
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Jean-Baptiste LASCARROU
Contact
jeanbaptiste.lascarrou@chu-nantes.fr
0240087386

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion